Kendall Capital Partners — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Bilayer TherapeuticsAug 2023SEC filingmedium confidence
BiotechCambridge, US
Thomas A. Collet(Executive Officer, Director)Carlo Traverso Giovanni(Director)
BoardJoshua Korzenik(Director)
Board seatRobert Langer· per SEC Form D · $1M raise · filed Aug 2023
OmniPulse BiosciencesDec 2023
A biotech company developing a multi-layered polymer delivery system for sustained-release vaccine and medication administration via single injection.
Cambridge, US
Board seatRobert Langer· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.